Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eusa Pharma, a transatlantic specialty pharmaceutical company, has completed its European launch of Caphosol for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care.
Subscribe to our email newsletter
Caphosol is also indicated for hyposalivation and xerostomia irrespective of the cause.
Bryan Morton, president and CEO of Eusa Pharma, said: “Caphosol’s introduction into the key French, German, Italian, Spanish, Benelux and UK markets, as well as a number of other EU countries, represents an important opportunity for Eusa to continue its rapid growth as the company commercializes its growing portfolio of specialty medicines on both sides of the Atlantic.
“Based on Eusa’s expanding market presence across the company’s areas of medical and geographic focus, we can increasingly compete with major players as a partner of choice for those seeking transatlantic commercial and late-stage development expertise.”